导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.87% | 2723/3266 |
| 近一周 | -3.70% | 3306/3690 |
| 近一月 | -3.35% | 1616/3663 |
| 近一季 | -6.51% | 1676/3534 |
| 近半年 | -12.17% | 2578/3357 |
| 近一年 | -18.12% | 2694/3056 |
| 近两年 | 34.09% | 1561/2167 |
| 近三年 | 17.69% | 1123/1638 |
| 成立以来 | 2.15% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.59% 4163/4961 |
-4.86% 3530/5312 |
- - |
- - |
| 2025 | 28.01% 1518/4813 |
5.13% 823/3635 |
12.14% 111/4076 |
17.71% 2448/4524 |
-7.75% 3835/4813 |
| 2024 | 13.11% 1174/3463 |
-2.93% 1454/2808 |
5.47% 193/3014 |
12.09% 2417/3129 |
-1.44% 1704/3463 |
| 2023 | -12.46% 1478/2656 |
-0.64% 1811/2280 |
-2.54% 606/2385 |
-5.94% 1399/2515 |
-3.89% 816/2655 |
| 2022 | -11.74% 255/2207 |
-11.01% 472/1919 |
5.20% 930/2016 |
-17.05% 1544/2113 |
13.64% 97/2208 |
| 2021 | -12.14% 1123/1822 |
2.79% 211/1255 |
4.27% 902/1330 |
-11.56% 1272/1466 |
-7.31% 1568/1822 |
| 2020 | 12.67% 810/1250 |
-14.64% 969/1028 |
11.47% 730/1067 |
5.20% 925/1164 |
12.56% 452/1184 |
| 2019 | 15.50% 692/1092 |
13.36% 701/739 |
-3.77% 402/788 |
-4.25% 764/850 |
10.58% 118/918 |
| 2018 | -19.77% 179/834 |
- - |
-1.74% 55/631 |
-1.50% 245/660 |
-10.36% 193/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 广发恒生中型股指数C VS. 长安沪深300非周期A(740101) |